Polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) versus R-ICE alone in second line treatment of diffuse large B-cell lymphoma (DLBCL)

Authors
Category Primary study
Registry of TrialsClinical Trials Information System
Year 2023
This article has no abstract
Epistemonikos ID: 74d0c4b140f29093d29bf0461c1eba6463a15252
First added on: Mar 21, 2025